Valuation: DRI Healthcare Trust

Capitalization 692M 596M 538M 516M 942M 63.55B 986M 6.36B 2.55B 30.48B 2.6B 2.54B 109B P/E ratio 2026 *
130x
P/E ratio 2027 * 24.6x
Enterprise value 1.07B 919M 830M 796M 1.45B 97.99B 1.52B 9.81B 3.93B 46.99B 4B 3.92B 168B EV / Sales 2026 *
5.48x
EV / Sales 2027 * 4.92x
Free-Float
97.91%
Yield 2026 *
3.47%
Yield 2027 * 4.33%
1 day+0.35%
1 week+1.12%
Current month+1.12%
1 month+4.91%
3 months+3.89%
6 months+17.28%
Current year+6.41%
1 week 16.02
Extreme 16.02
17.31
1 month 15.5
Extreme 15.5
17.31
Current year 15
Extreme 15
17.31
1 year 10.7
Extreme 10.7
17.31
3 years 7.16
Extreme 7.16
17.43
5 years 5.83
Extreme 5.83
17.43
10 years 5.83
Extreme 5.83
17.43
Manager TitleAgeSince
Chief Executive Officer 63 2024-07-07
Director of Finance/CFO - 2025-09-30
Director TitleAgeSince
Chairman 63 2021-01-21
Director/Board Member 51 2020-05-31
Director/Board Member 66 2021-01-21
Change 5d. change 1-year change 3-years change Capi.($)
+0.35%+1.12%+41.79%+129.84% 692M
+0.72%-5.86%+13.89%+218.81% 885B
+0.32%-3.23%+44.22%+56.01% 579B
-0.96%-0.85%+7.38%+50.47% 407B
-2.93%-7.03%+11.14%+27.55% 350B
-1.25%-5.55%+22.14%+55.83% 302B
-1.85%-6.70%+20.11%+33.64% 301B
-0.24%-6.49%+22.33%+4.06% 286B
+0.53%-4.80%+13.75%+61.56% 199B
-0.83%-3.37%+22.59%+79.29% 179B
Average -0.61%-4.32%+21.93%+71.71% 348.94B
Weighted average by Cap. -0.47%-4.59%+20.28%+89.10%

Financials

2026 *2027 *
Net sales 194M 168M 151M 145M 265M 17.87B 277M 1.79B 717M 8.57B 730M 714M 30.65B 203M 175M 158M 152M 277M 18.7B 290M 1.87B 750M 8.97B 764M 747M 32.06B
Net income 5.76M 4.96M 4.48M 4.3M 7.84M 529M 8.2M 52.96M 21.22M 254M 21.6M 21.14M 907M 14.43M 12.44M 11.23M 10.78M 19.65M 1.33B 20.57M 133M 53.2M 636M 54.17M 53.01M 2.27B
Net Debt 375M 323M 292M 280M 510M 34.43B 534M 3.45B 1.38B 16.51B 1.41B 1.38B 59.05B 309M 267M 241M 231M 421M 28.42B 441M 2.85B 1.14B 13.63B 1.16B 1.14B 48.75B
Logo DRI Healthcare Trust
DRI Healthcare Trust is a Canada-based company engaged in providing financing to advance innovation in the life sciences industry. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It acquires approximately 70 royalties on 45-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda, Stelara, and Xenpozyme. Its portfolio includes Empaveli, Eylea, Natpara, Omidria, Rydapt, Simponi, Syfovre, Vonjo, Zejula and Zytiga. Its therapeutic areas include influenza, endocrinology, ophthalmology, dermatology, oncology, neurology, autoimmune diseases, heme-onc, lysosomal storage disorder, respiratory diseases, oncology and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis, Johnson & Johnson, Sanofi S.A., and others.
Employees
-
Date Price Change Volume
26-03-06 17.10 $ +0.35% 104,798
26-03-05 17.04 $ +2.22% 31,942
26-03-04 16.67 $ +1.96% 9,633
26-03-03 16.35 $ -2.50% 31,647
26-03-02 16.77 $ -0.83% 21,205
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.56USD
Average target price
15.51USD
Spread / Average Target
+23.55%

Quarterly revenue - Rate of surprise